Myriad Reaches New 52-Week High (MYGN)

NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Friday as it is currently trading at $25.92, above its previous 52-week high of $25.89 with 869,319 shares traded as of 1:30 p.m. ET. Average volume has been 731,200 shares over the past 30 days.

Myriad has a market cap of $1.98 billion and is part of the services sector and diversified services industry. Shares are up 13.5% year to date as of the close of trading on Thursday.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company has a P/E ratio of 19.5, above the average diversified services industry P/E ratio of 19.1 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Myriad as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Myriad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.